Retrospectively Analyzing the Use of CDK4/6 Inhibitors to Treat Adult Female Patients with Metastatic Breast Cancer

2020 Year in Review - Breast Cancer - Breast Cancer

The majority of patients with metastatic breast cancer receiving treatment with CDK4/6 inhibitors had progression-free survival, behaving similarly when used as first-line therapy or after adjuvant hormonal therapy.

Silvia Comis, MD, Senior Medical Director, Oncology-Therapeutic Science and Strategy Unit, IQVIA, Milan, Italy, and colleagues used US open health claims and prescription data to examine the pattern of behavior of CDK4/6 inhibitor combinations as first-line therapy or following adjuvant hormonal therapy in adult females with de novo metastatic breast cancer.

The researchers examined metastatic breast cancer between 2015 and 2019, in adult female patients aged >18 years. Based on their first treatment, women were classified into 3 groups (group 1, hormonal; group 2, CDK4/6 inhibitor combinations; and group 3, everolimus combination).

The percentage of patients who switched to next therapy was 3.2% (1200 patients) of the 37,351 patients receiving CDK4/6 inhibitors as first-line therapy or following adjuvant hormonal therapy for advanced or metastatic diseases. For the majority of patients, in 87% of cases, changing therapy occurred within a 2-year period, and those patients who continued with first-line therapy did so for an extended period of time.

Compared with the overall CDK4/6 inhibitor population in groups 1 and 2, no statistically significant difference was apparent in the treatment pattern. However, within the first year of treatment, 90% of patients in group 3 compared with the overall patient population receiving CDK4/6 inhibitors switched to chemotherapy (P = .02).

A detailed analysis found that the overwhelming majority (90%) of patients receiving CDK4/6 inhibitors remained on therapy for approximately 1 year, with a small percentage of patients (2%) extending treatment to between 2 and 4.5 years.

The researchers concluded that for the period analyzed, 95% of patients receiving CDK4/6 inhibitors had progression-free survival. Overall, when used as first-line therapy or following adjuvant hormonal therapy, patients receiving CDK4/6 inhibitors had comparable patterns of behavior.

Source: Comis S, Kandasamy T, Perrin AJ, et al. A retrospective analysis of CDK4/6 inhibitors among adult female patients with metastatic breast cancer. J Clin Oncol. 2020;38(15_suppl). Abstract e13028.

Related Items
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape published on January 11, 2024 in Breast Cancer
Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer
Emily M. Beard, RN, BSN, OCN, CBCN, Abbey J. Kaler, MS, APRN, FNP-C, Mohammed A. Jaloudi, MD
Best Practices in Ovarian Function Suppression in Breast Cancer published on December 21, 2023 in Breast Cancer
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report
Blake T. Robbins, PharmD, MBA , Alexander M. Kreimer, PharmD, BCPS , Reema A. Patel, MD, Allison R. Butts, PharmD, BCOP
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Tumor Lysis Syndrome, Breast Cancer
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: